Patents by Inventor Seetharaman Jayaraman
Seetharaman Jayaraman has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140288266Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: ApplicationFiled: March 18, 2014Publication date: September 25, 2014Applicant: Aurinia Pharmaceuticals, Inc.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jürgen Mair, Jean-Michel Adam, Bruno Lohri
-
Publication number: 20110092669Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: ApplicationFiled: December 23, 2010Publication date: April 21, 2011Applicant: ISOTECHNIKA INC.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jurgen Mair, Jean-Michel Adam, Bruno Lohri
-
Publication number: 20100062976Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: ApplicationFiled: September 8, 2009Publication date: March 11, 2010Applicant: ISOTECHNIKA INC.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jurgen Mair, Jean-Michel Adam, Bruno Lohri
-
Publication number: 20070087963Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: ApplicationFiled: October 13, 2006Publication date: April 19, 2007Inventors: Selvaraj Naicker, Randall Yatscoff, Robert Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jurgen Mair, Jean-Michel Adam, Bruno Lohri
-
Patent number: 7141648Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: GrantFiled: October 17, 2002Date of Patent: November 28, 2006Assignee: Isotechnika Inc.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jürgen Mair, Jean-Michel Adam, Bruno Lohri
-
Publication number: 20060223743Abstract: Isolated metabolites of the cyclosporine analog ISA247 are disclosed, including in vitro methods for their preparation. The metabolites comprise a chemical modification of ISA247, wherein the modification is at least one reaction selected from the group consisting of hydroxylation, N-demethylation, diol formation, epoxide formation, and intramolecular cyclization phosphorylation, sulfation, glucuronide formation and glycosylation. Methods of preparation include semi-synthetic methods, wherein metabolites of ISA247 are produced from the microsomal extracts of animal liver cells, or from cultures using microorganisms, and completely synthetic methods, such as chemically modifying the parent compound or isolated metabolites using organic synthetic methods.Type: ApplicationFiled: December 19, 2005Publication date: October 5, 2006Inventors: Mark Abel, Robert Foster, Derrick Freitag, Daniel Trepanier, Shin Sugiyama, Seetharaman Jayaraman, Randall Yatscoff
-
Publication number: 20040220091Abstract: A new process for the preparation of a cyclosporin A analog of formula I 1Type: ApplicationFiled: April 5, 2004Publication date: November 4, 2004Inventors: Jean-Michel Adam, Mark Abel, Seetharaman Jayaraman
-
Publication number: 20030212249Abstract: The invention is directed to isomeric mixtures of cyclosporine analogues that are structurally similar to cyclosporine A. The mixtures possess enhanced efficacy and reduced toxicity over the individual isomers and over naturally occurring and other presently known cyclosporines and cyclosporine derivatives. Embodiments of the present invention are directed toward cis and trans-isomers of cyclosporin A analogs referred to as ISATX247, and derivatives thereof. ISATX247 isomers and alkylated, arylated, and deuterated derivatives are synthesized by stereoselective pathways where the particular conditions of a reaction determine the degree of stereoselectivity. Stereoselective pathways may utilize a Wittig reaction, or an organometallic reagent comprising inorganic elements such as boron, silicon, titanium, and lithium. The ratio of isomers in a mixture may range from about 10 to 90 percent by weight of the (E)-isomer to about 90 to 10 percent by weight of the (Z)-isomer, based on the total weight of the mixture.Type: ApplicationFiled: October 17, 2002Publication date: November 13, 2003Applicant: Isotechnika, Inc.Inventors: Selvaraj A. Naicker, Randall W. Yatscoff, Robert T. Foster, Mark Abel, Seetharaman Jayaraman, Hans-Jurgen Mair, Jean-Michel Adam, Bruno Lohri